Agenus, Inc. (AGEN)
7.67
-0.42
(-5.19%)
USD |
NASDAQ |
Aug 24, 16:00
7.67
0.00 (0.00%)
After-Hours: 20:00
Agenus Net Income (Quarterly) : -0.567M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.567M |
| March 31, 2026 | 39.21M |
| December 31, 2025 | -10.61M |
| September 30, 2025 | 63.91M |
| June 30, 2025 | -30.01M |
| March 31, 2025 | -26.37M |
| December 31, 2024 | -46.81M |
| September 30, 2024 | -67.21M |
| June 30, 2024 | -54.80M |
| March 31, 2024 | -63.45M |
| December 31, 2023 | -48.58M |
| September 30, 2023 | -64.53M |
| June 30, 2023 | -73.43M |
| March 31, 2023 | -70.89M |
| December 31, 2022 | -74.10M |
| September 30, 2022 | -56.72M |
| June 30, 2022 | -49.24M |
| March 31, 2022 | -50.60M |
| December 31, 2021 | -67.61M |
| September 30, 2021 | 177.28M |
| June 30, 2021 | -83.99M |
| March 31, 2021 | -54.40M |
| December 31, 2020 | -37.73M |
| September 30, 2020 | -51.65M |
| June 30, 2020 | -48.24M |
| Date | Value |
|---|---|
| March 31, 2020 | -45.27M |
| December 31, 2019 | -30.85M |
| September 30, 2019 | -46.28M |
| June 30, 2019 | -51.87M |
| March 31, 2019 | 17.44M |
| December 31, 2018 | -48.85M |
| September 30, 2018 | -33.73M |
| June 30, 2018 | -25.20M |
| March 31, 2018 | -54.26M |
| December 31, 2017 | -35.04M |
| September 30, 2017 | -36.84M |
| June 30, 2017 | -31.71M |
| March 31, 2017 | -17.10M |
| December 31, 2016 | -26.12M |
| September 30, 2016 | -40.77M |
| June 30, 2016 | -28.32M |
| March 31, 2016 | -31.78M |
| December 31, 2015 | -15.61M |
| September 30, 2015 | -13.12M |
| June 30, 2015 | -40.41M |
| March 31, 2015 | -18.74M |
| December 31, 2014 | -25.98M |
| September 30, 2014 | -8.109M |
| June 30, 2014 | -7.762M |
| March 31, 2014 | -0.3575M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -47.32M |
| Novavax, Inc. | -53.39M |
| Fate Therapeutics, Inc. | -30.16M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| EPS Diluted (Quarterly) | -0.0146 |
| Enterprise Value | 609.42M |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 34.56% |
| Operating Earnings Yield | 12.66% |
| Normalized Earnings Yield | 13.01 |